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Background: Tuberculosis (TB) treatment may present significant hematological disorder and some anti-TB drugs
also have serious side effects. Although many other diseases may be reflected by the blood and its constituents,
the abnormalities of red cells, white cells, platelets, and clotting factors are considered to be primary hematologic
disorder as a result of tuberculosis treatment. The aim of this study was to determine hematological profiles of TB
patients before and after intensive phase treatment.
Objective: The aim of this study was to determine hematological profiles of TB patients before and after intensive
phase treatment.
Methods: Smear positive new TB patients were recruited successively and socio-demographic characteristics were
collected using pre-tested questionnaire. About 5 ml of venous blood was collected from each patient and the
hematological profiles were determined using Mindry BC 3000 plus automated hematology analyzer.
Result: The hematological profiles of TB patients showed statistically significant difference in hematocrit (38.5 % versus
35.7 %), hemoglobin (12.7 g/lversus11.8 g/l) and platelet (268 × 103/μlversus239 × 103/μl) values of patients before
initiation of treatment and after completion of the intensive phase of tuberculosis treatment, respectively
(P < 0.05). The red cell distribution width (RDW) of treatment naïve TB patients was by far lower (17.6 ± 7.09 %)
than the corresponding RDW (31.9 ± 5.19 %) of intensive phase treatment completed patients. Among TB patients that
had high platelet distribution width (PDW) (n = 11) before initiation of TB treatment, 10 demonstrated lower PDW
values after completion of the intensive phase. There was no significant difference on total white blood cell
count among TB patients before and after completion of the 2 month treatment.
Conclusion: The levels of hemoglobin, hematocrit and platelet count of the TB patients were significantly
lowered after completion of the intensive phase of TB treatment. Significant variation of the RDW and PDW
were also observed among treatment naïve and treatment completed patients. Hematological abnormalities
resulted from TB treatment should be assessed continuously throughout the course of tuberculosis therapy.
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Tuberculosis (TB) is a contagious disease that can affect
almost any tissue and organs of the human body but
mainly cause infection of the lungs [1]. Tuberculosis is a
major public health problem throughout the world.
About a third of the world’s population is estimated to
be infected with tubercle bacilli and hence at risk of de-
veloping active TB disease. The burden of TB is highest
in Africa, Asia, India and China together accounting for
almost 40 % of the world’s TB cases [2]. About 2.4 mil-
lion new TB cases and 540,000 TB-related deaths occur
in sub-Saharan Africa annually [3]. Ethiopia is among
the countries most heavily affected by TB [4]. The an-
nual TB incidence of Ethiopia is estimated to be 341/
100,000. Tuberculosis mortality rate is 73/100,000 and
the prevalence of all forms of TB is estimated to be 546/
100,000 [5].
TB is a curable disease although drug resistance is one
of the major challenges in the treatment, prevention and
control of the disease. However, the use of anti-TB drugs
is not free from side effects. Allergic reactions, fever,
rash, vasculitis, nausea, vomiting, hepatotoxicity, hepato-
cellular inflammation, peripheral neuropathy and others
are some of the common side effects associated with TB
treatment [6]. In addition, a wide range of hematological
abnormalities has been reported as a result of adminis-
tration of anti-TB drugs. The major hematological dis-
order due to anti-TB drug is aplastic anemia. Aplastic
anemia is a hypo- regenerative bone marrow disorder
characterized by a reduction in the amount of haemopoi-
tic bone marrow and pancytopenia. It has been reported
that pancytopenia due to aplastic anemia of moderate se-
verity was observed in a patient while receiving anti-
tuberculosis therapy, probably caused by an idiosyncratic
reaction to streptomycin. Although the total leukocyte
and platelet counts could be depressed after cessations of
drugs, physicians rarely suspect anti-tuberculosis induced
hematological complications which may have fatal conse-
quences [7].
Hematological disorders arise through a variety of mech-
anisms and etiologies. Drug-induced hematological disor-
ders can span almost the entire spectrum of hematology,
affecting red cells, white cells, platelets, and the coagulation
system. The wide spectrum of drug-induced hematologic
syndromes is mediated by a variety of mechanisms, in-
cluding immune effects, interactions with enzymatic
pathways, and direct inhibition of hematopoiesis. Drug-
induced syndromes include hemolytic anemia, red cell
aplasia, sideroblastic anemia, megaloblastic anemia,
polycythemia, aplastic anemia, leukocytosis and others.
There are four possible relationships of tuberculosis to
hematologic disease. These are the hematologic disease
predisposes to tuberculosis reactivation. Drugs may cause
idiosyncratic reactions, malabsorption, interference withiron metabolism, and hemolysis in patients with red blood
cell enzyme deficiencies. Idiosyncratic reactions mani-
fested by depression of any or all of the three cellular
blood elements (white cells, red cells and platelets) to-
gether with the coagulation system may be caused by any
of the anti-tuberculosis drugs [8, 9].
The magnitude of drug induced hematological abnor-
malities had been investigated in different parts of the
world. For example, leucopenia as a result of rifampicin
and isoniazid therapy was reported in Japan [10]. Anti-
TB drug induced normocytic normochromic anemia
was the most common abnormality observed in Malaysia
[11] and a 74 % prevalence of anemia together with 26 %
Leukocytosis, 24 % Thrombocytosis was reported in India
[12]. In a study conducted in South Africa, a 15 % leuco-
penia, 23 % thrombocytopenia and 87 % lymphopenia was
reported as a result of anti-TB drug treatment [13]. By an-
other study conducted in Nigeria, anti-TB drug induced
hematological abnormality were reported 93.6, 22.3, 45.2
and 4.8 % for anemia, leukocytosis, neutrophilia, and lym-
phopaenia, respectively [14]. Moreover, in Tanzania an
86 % anti-TB drug induced anemia was reported [15].
Different reports showed that altered hematopoiesis
occurs in TB patients. Hematological changes associated
with tuberculosis treatments have been investigated in
many parts of the world. However, to the best of our
knowledge, there is no comprehensive study assessed
the hematological abnormalities among TB patients in
Ethiopia in general and in Gondar in particular. Hence,
this study was designed to determine the effect of anti-
TB drugs on hematological profile among TB patients.
In the present study, hematological findings amongTB
patients before initiation and after completion of the in-
tensive phase of tuberculosis treatment were assessed.Methods
Study design, area and setting
A longitudinal prospective study was conducted from
February to June 2014 at the University of Gondar
(UoG) hospital, Northwest Ethiopia. The hospital is
found in Gondar town. Gondar town is located in the
North Gondar Zone of the Amhara Region, North of
Lake Tana, Northwestern Ethiopia, and 748 km far from
Addis Ababa. The town has a latitude and longitude of
12°36′N 37°28′E with an elevation of 2133 m above sea
level. Based on figures from the Central Statistical
Agency in 2008, Gondar has an estimated total popula-
tion of 231,977. University of Gondar hospital is a refer-
ral hospital for Northwestern Ethiopia with more than
400 beds serving a population of about 5 million. The
Hospital is one of the biggest tertiary level referral and
teaching hospitals in the region. A large number of
people from the surrounding zones and nearby regions
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treatment.
Populations
The source population was all TB suspected patients
(both pulmonary and extra pulmonary) attending for
health service at the University of Gondar Hospital. The
study population were smear positive pulmonary tuber-
culosis patients and all confirmed extra-pulmonary TB
patients who took all the intensive phase of treatment at
the Directly Observed Treatment Short course (DOTS)
clinic of University of Gondar hospital during the study
period. In this study, TB patient less than 5 years of age
and greater than 65 years of age, retreatment cases, pa-
tient with known organ impairment, malignant cases
(cancer and chronic patients) and HIV patients were ex-
cluded from the study.
Sample size determination and sampling technique
Time delimited consecutive sampling technique was
employed to recruit the study subjects. All newly diag-
nosed TB patients who were confirmed for tubercu-
losis infection and seeking for anti-TB treatment at the
University of Gondar Teaching Hospital DOTS clinic
during the study period were included. By using the in-
clusion and exclusion criteria’s set for the study, a total
of 168 new TB patients were recruited and involved in
this study.
Socio-demographic data
Socio-demographic characteristics such as age, sex,
marital status, residence and clinical information such as
WHO clinical stage, use of myelo-suppressive drugs, loss
of appetite, weight loss, night sweats and fever were
gathered using pre-tested and structured questionnaire.
A trained clinical nurse and laboratory technologist work-
ing at the DOTS clinic of the University of Gondar hos-
pital collected the socio-demographic characteristics of
the TB patients.
Sputum sample collection and microscopy
Sputum samples were collected using dry, clean, leak
proof, translucent and screw-capped plastic containers
with a capacity of 30 ml. Smears were prepared and air
dried then stained with Ziehl-Neelsen (ZN) stain. Briefly,
smears were genteelly heat fixed and each smear was
flooded with carbolfuchsin solution. On each prepar-
ation, heat was applied until steaming and allowed to
stand for 5 min. After washing with tap water, smear
was decolorized with acid alcohol for 1 min and washed
with tap water and counter stained with methylene blue
for 30 s, washed and air dried. Slides were examined
under 100× oil immersion objective with bright field il-
lumination. Microscopy results were recorded followingthe WHO reporting methods as negative, actual number
of acid-fast bacilli (AFB), 1+, 2+ and 3 + .
Blood sample collection and determination of
hematological parameters
About 5 ml of venous blood was collected aseptically by
using EDTA tube from each of the selected study sub-
jects. following collection, the EDTA tube was labeled
with code number. The blood sample was collected from
each study subject before initiation of anti-TB drugs and
after completion of the 2 month intensive phase treat-
ment. Hematologic profiles such as Red blood cell count,
hemoglobin level, hematocrit (HCT), Red blood cell in-
dices such as mean corpuscular volume (MCV), mean
corpuscular haemoglobin (MCH), mean corpuscular
haemoglobin concentration (MCHC), Red cell distribu-
tion width (RDW), total white blood cell count (WBC),
WBC differential count, Platelet count, Mean Platelet
Volume (MPV) and platelet cell distribution width (PDW)
were determined using Mindray automated hematology
analyzer following the manufacturers instruction and the
Standard Operational Procedures (SOP) of the University
of Gondar hospital laboratory.
Quality control
The reliability of the study findings were guaranteed by
implementing quality control (QC) measures throughout
the whole process of the laboratory work. All materials,
equipment and procedures were adequately controlled.
Blood samples were collected free of hemolysis, clot,
with sufficient quantity (5 ml) and correctly labeled with
patients identification number. The performance of the
hematology analyzer was check by running normal, low
and high blood controls. During a condition where flags
were found with automation hematological parameters,
manual differential count was performed. Sputum sam-
ples with an AFB score of 1+ (n = 10) was used to assess
the reliability of microscopic examinations. These sam-
ples were stained by Ziehl-Neelsen stain and examined
by two laboratory technologists blinded from each other.
The coefficient of variation (CV) was found 0.016 which
shows that the result of the two laboratory technologists
was 99.984 % consistent. The questionnaire was pre-
pared in English, translated to local Amharic language
and then translated back to English to check for
consistency. Data on Socio-demographic and TB related
medical history were collected by trained nurses under
the supervision of the investigators.
Data analysis
Data were checked, sorted, categorized and coded manu-
ally then transferred to SPSS version 20 statistical pack-
ages for analysis. Frequencies and cross tabulations were
used to summarize descriptive statistics. Paired t test
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values before initiation and after completion of the in-
tensive phase of tuberculosis treatment. A P values less
than 0.05 were considered statistically significant.
Ethical consideration
Ethical approval was obtained from an ethical review
committee organized by the School of Biomedical and
Laboratory Sciences which was mandated by the College
of Medicine and health Sciences, University of Gondar.
A permission and support letter was also obtained from
University of Gondar hospital and both verbal and writ-
ten consent was obtained from each participant. All the
consent procedures were approved by the ethical ap-
proval committee of the School of Biomedical and
Laboratory Sciences. In the case of children, both verbal
and written consent were taken from the guardian that
was also approved by the ethical review committee. The
purpose and importance of the study was explained to
each study participants. To ensure confidentiality of par-
ticipants information, anonymous typing was applied
where by the name of the participant and any identifier
of participants were not written on the questionnaire,
and during the interview to keep the privacy, they were
interviewed alone. The laboratory findings of each study
participant were communicated with the responsible
clinician assigned at TB clinic. Above all the data was
collected after full written consent was obtained from
each study participates.
Results
Characteristics of the study participants
A total of 168 HIV negative new TB patients were in-
cluded in this study. Ninety six (56.5 %) of the TB pa-
tients were males and the other 73 (43.5 %) were
females. The mean age of the study participants was
34.8 ± 15.3 years ranging from 5 to 65 years. Sixty-two
(36.9 %) TB patient were within the age group 5–25, 62
(36.9 %) within the age group 26–44 and the other 44
(26.2 %) within 45–65 years of age. Forty-seven percent
(n = 79) were urban dwellers and the other 53 % (n = 89)
were living in rural areas. The clinical and laboratory
data of the TB patients showed that 87 (51.8 %) and 81
(48.2 %) were pulmonary and extra pulmonary cases.
Association between hematological parameters with the
age and sex of the TB patients before and after
completion of the intensive phase treatment
Tuberculosis confirmed patients were investigated to as-
sess their hematological profile prior initiation of anti-
TB treatment and after completion of the intensive
phase treatment. The hematological profiles assessed
were red blood cell count, hemoglobin concentration,
hematocrit, red cell indices, total white blood cell count,white blood cell differential count, red blood cell distri-
bution width, platelet distribution width, platelet count
and mixed cells (eosinophile, monocyte and basophile)
count. Analysis of the demographic characteristics of the
TB patients such as age and sex versus hematological
parameters demonstrated that there was significant dif-
ference on Hgb and Hct concentrations (P < 0.001) be-
fore initiation and after completitions of the intensive
phase treatment. In addition, a significant difference on
RBC among patients with the age group 45–65 years
was observed (P = 0.030). The RDW-CV parameter of fe-
male patients and the PLT count of male patients were
also significantly different (P = 0.002 and 0.031 respect-
ively) (Table 1). However, there was no significant differ-
ence in WBC parameters and PDW versus the age and
sex of the TB patients.
Assessment of anemia
The magnitude of anemia among TB patients before ini-
tiation and after completion of the intensive phase of
treatment was assessed using red blood cell count
(RBC), hemoglobin (Hgb) and hematocrit (Hct) values.
The average RBC of the TB patients before initiation of
anti-TB treatment was relatively similar to that of RBC
after completion of the intensive phase of tuberculosis
treatment (4.25 × 103 ± 0.83 versus 4.42 × 103 ± 0.824, re-
spectively) (Table 2). Many of the TB patients that had
normal RBC before initiation of tuberculosis treatment
(n = 72) demonstrated also normal RBC after completion
of the intensive phase (n = 69) of treatment. However,
54 % of the TB patients had lower RBC before initiation
and after completion of the intensive phase of treatment.
Nevertheless, data showed no statistically significant dif-
ference on the RBC of TB patients before initiation and
after completion of the intensive phase of tuberculosis
treatment. The average Hgb concentration of the TB pa-
tients before initiation of tuberculosis treatment was
slightly higher (12.7 ± 2.09 g/dl) than the corresponding
Hgb concentration determined after completion of the
intensive phase of treatment (11.8 ± 1.68 g/dl). Similarly,
the average packed cell volume (Hct) was also relatively
higher before initiation of treatment (38.5 ± 2.42 %) than
the corresponding concentration after completion of the
2 month treatment (35.7 ± 2.31 %). In this study, 55 % of
the TB patients (n = 92) had low Hgb concentration and
the Hct values of 86 TB patients (51 %) was found low
before initiation of anti-tuberculosis treatment. The pro-
portion of TB patients with low Hgb and Hct concentra-
tion was by far increased (72 %) after completion of the
intensive phase of TB treatment. Among the TB patients
that had higher Hct concentration (n = 13) before initi-
ation of anti-TB treatment, only 4 resulted similarly
higher concentration. On the other hand, among 69 and
76 patients that had normal Hct and Hgb concentration
Table 1 Hematological parameters that demonstrated significant difference based on the age and sex of TB patients before
initiation of anti-TB drugs compared with after completion of the intensive phase of treatment
Before treatment After treatment P-value
RBC × 106/ μl Sex Male 4.27 ± 0.92 4.43 ± 0.92 0.235
Female 4.24 ± 0.72 4.42 ± 0.68 0.143
Age 5 – 25 4.26 ± 0.77 4.42 ± 0.89 0.320
26 – 44 4.37 ± 0.75 4.33 ± 0.68 0.747
45 – 65 4.09 ± 1.01 4.58 ± 0.92 0.030*
Hgb (g/dl) Sex Male 12.7 ± 2.1 11.8 ± 1.5 0.000*
Female 12.8 ± 2.1 11.8 ± 1.9 0.000*
Age 5 – 25 12.9 ± 2 11.8 ± 1.8 0.000*
26 – 44 12.9 ± 1.8 12 ± 1.4 0.001*
45 – 65 12.4 ± 2.5 11.5 ± 1.8 0.000*
HCT (%) Sex Male 38.6 ± 6 35.8 ± 4.4 0.000*
Female 38.9 ± 5.5 35.7 ± 5.4 0.000*
Age 5 – 25 39.1 ± 5.7 35.7 ± 5.5 0.000*
26 – 44 38.9 ± 4.9 36.6 ± 4 0.001*
45 – 65 37.9 ± 6.8 34.7 ± 5 0.000*
MCV (fl) Sex Male 88.4 ± 6.9 89.4 ± 9.1 0.036*
Female 89.4 ± 6.7 90.9 ± 5.1 0.143
Age 5 – 25 89.4 ± 7.3 90.2 ± 5.1 0.486
26 – 44 88.3 ± 5.8 91.2 ± 5.8 0.013*
45 – 65 88.7 ± 7.6 90.4 ± 5.2 0.241
MCH (pg) Sex Male 28.9 ± 3.3 29.6 ± 2.3 0.143
Female 29.2 ± 2.6 30.1 ± 2 0.040*
Age 5 – 25 29.3 ± 3 29.7 ± 2.1 0.427
26 – 44 29.1 ± 3.1 29.7 ± 2.5 0.253
45 – 65 28.5 ± 3 30 ± 2 0.012*
MCHC (%) Sex Male 32.7 ± 2 32.7 ± 1.3 0.878
Female 32.6 ± 1.4 33.1 ± 1.1 0.049*
Age 5 – 25 32.6 ± 1.6 32.9 ± 1.3 0.357
26 – 44 33 ± 1.9 32.7 ± 1.3 0.390
45 – 65 32.2 ± 1.6 33.1 ± 1 0.003*
RDW CV (%) Sex Male 14.4 ± 1.4 14.2 ± 1.2 0.311
Female 14.5 ± 1.7 13.9 ± 1.2 0.02*
Age 5 – 25 14.4 ± 1.4 14.1 ± 1.3 0.143
26 – 44 14.3 ± 1.4 14.1 ± 1.2 0.477
45 – 65 14.6 ± 1.8 14 ± 1.1 0.059
PLT × 103/μl Sex Male 267 ± 106 232 ± 109 0.031*
Female 270 ± 101 250 ± 86 0.169
Age 5 – 25 258 ± 105 250 ± 116 0.697
26 – 44 274 ± 101 246 ± 72 0.085
45 – 65 275 ± 105 216 ± 108 0.006*
* = significant association
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Table 2 Hematological profiles of tuberculosis patients before and after initiation of anti-TB treatment at University of Gondar Teaching
hospital, 2014
Variable Before treatmentof TB Mean (SD) After treatmentof TB Mean (SD) P-Value
RBC/μl 4.25 × 106 (0.83) 4.42 × 106 (0.824) 0.072
WBC/ μl 7.5 × 103 (3.76) 7.08 × 103 (3.27) 0.224
Hgb (g/dl) 12.7 (2.09) 11.8 (1.68) 0.000*
HCT (%) 38.5 (2.42) 35.7 (2.31) 0.000*
MCV (fl) 88.8 (6.8) 89.7 (8.4) 0.268
MCH (Pg) 30.13 (5.0) 29.03 (3.0) 0.018*
MCHC (g/dl) 30.13 (2.91) 29.43 (7.1) 0.000*
RDW-CV 17.6 (7.09) 31.9 (5.19) 0.000*
PLT/ μl 268 × 103 (103.2) 239.93 (99.8) 0.01*
PDW 17.01 (4.79) 15.7 (0.61) 0.001*
Lymphocyte 1.96 × 103 (0.94) 2.08 × 103 (1.36) 0.375
Mixed cell 0.74 × 103 (0.422) 0.69 × 103 (0.425) 0.272
Neutrophil 4.37 × 103 (2.42) 4.08 × 103 (2.31) 0.230
RBC red blood cell, WBC White blood cell, HCT Haematocrit, HGB Haemoglobin, MCV mean corpuscular volume, MCH mean haemoglobin, MCHC mean
haemoglobin concentration, RDW-CV red cell distribution width, PLT platelet, PDW Platelet distribution width, fl femto litter (10−15L), pg pico-gram (10−12g),
* significant association
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demonstrated normal concentrations respectively after
completion of the intensive phase treatment (Table 3).
Moreover, data showed a significant decreased level of
Hgb concentration and Hct value after completion of
the 2 month tuberculosis treatment compared to the
pre-treatment level (P = 0.00).Leukocytosis versus leukopenia
The average total WBC of TB patients before treatment
(7.5 × 103 ± 3.76) was slightly lower than the corre-
sponding average WBC after completion of the 2 month
treatment (7.08 × 103 ± 3.27). The total WBC of 24 TB
patients (14.3 %) enumerated before initiation of TB
treatment was low but that of 115 (68.5 %) and 29
(17.3) patients were normal and high, respectively. The
proportion of tuberculosis patients with low WBC was
slightly raised 18.5 % (n = 31) when examined after
completion of the intensive phase of treatment. How-
ever, there was no statistically significant difference on
total WBC among TB patients before initiation and
after completion of the 2 month tuberculosis treat-
ment. The lymphocyte, neutrophil and mixed cell (eo-
sinophil, monocyte and basophil) differential WBC
count of the TB patients showed no statistically signifi-
cant difference among TB patients before and after
initiation of tuberculosis treatment. However, the pro-
portion of TB patients with high neutrophil count was
raised from 7.7 % (n = 13) of treatment naïve phase to
14.3 % (n = 24) after completion of the 2 month tuber-
culosis treatment.Association of tuberculosis treatment with platelet count
The mean thrombocyte count among TB patients be-
fore administration of anti-TB drugs was 268 × 103 ±
103.2. The corresponding platelet counts among TB pa-
tients after completion of the 2 month treatment was
slightly lower (239 × 103 ± 99.8). However, data showed
no statistically significant difference on platelet count
among TB patients before initiation and after comple-
tion of the intensive phase tuberculosis treatment. The
proportion of TB patients with low platelet count was
slightly increased after completion of tuberculosis treat-
ment (n = 25; 14.9 %) compared to the corresponding
platelet count among tuberculosis treatment naïve pa-
tients (n = 22; 13.1 %). On the other hand, significantly
reduced proportion of TB patients with high platelet
count was observed (8.9 %; n = 15) after completion of
the intensive phase of TB treatment compared to the
proportion of TB patients with high platelet count
(19.6 %; n = 33) among treatment naïve TB patients.
Moreover, data showed significant difference in the pro-
portion of TB patients with both low and high platelet
count after completion of the 2 month treatment com-
pared with treatment naïve patients (P = 0.01).
Red blood cell indices during tuberculosis treatment
The average MCV of the TB patients before initiation
of tuberculosis treatment and after completion of the
2 month treatment was nearly similar (88.8 ± 6.8 versus
89.7 ± 8.4, respectively). A slightly reduced MCH
(29.03 ± 3.0) was observed after completion of the in-
tensive phase tuberculosis treatment compared with the
average MCH before initiation of treatment (30.13 ± 5.0).
Table 3 The proportion of TB patients with low, normal and high hematological profile before initiation and after completion of the
intensive phase tuberculosis treatment at University of Gondar hospital, 2014
Parameters Category Before TB treatment After TB treatment Reference Intervals P-Value
RBC Low 91 (54.2) 92 (54.8) 0.92
Normal 72 (42.9) 69 (41.1) M = 4.5-6.2 × 106/ μl
F = 4.0 -5.5 × 106/μl
High 5 (3) 7 (4.2)
WBC Low 24 (14.3) 31 (18.5) 0.262
Normal 115 (68.5) 113 (67.3) 4.0 – 10.0 × 103/μl
High 29 (17.3) 24 (14.3)
HCT Low 86 (51.2) 122 (72.6) 0.000*
Normal 69 (41.1) 42 (25.0) M = 40 -52 %
F =36 – 47 %
High 13 (7.7) 4 (2.4)
HGB Low 92 (54.8) 121 (72) 0.000*
Normal 76 (45.2) 47 (28) M = 13 – 18 g/dl
F = 12–16 g/dl
High 0 (0) 0 (0)
MCV Low 13 (7.7) 10 (6) 0.589
normal 129 (76.8) 130 (77.4) 80 – 100 fl
high 26 (15.5) 28 (16.7)
MCH low 37 (22) 18 (10.7) 0.000*
Normal 96 (57.1) 105 (62.5) 27 – 32 pg
High 35 (20.8) 45 (26.8)
MCHC low 75 (44.6) 163 (98.2) 0.000*
normal 90 (53.6) 3 (1.8) 31.5 – 36 g/dl
RDW_CV Normal 118 (70.2) 9 (5.4) 11.5 - 14.5 % 0.000*
high 50 (29.8) 159 (94.6)
PLT low 22 (13.1) 25 (14.9) 0.01*
normal 113 (67.3) 128 (76.2) 150 - 450 × 103/μl
High 33 (19.6) 15 (8.9)
PDW Normal 157 (93.5) 167 (99.4) 10 -17 % 0.000*
high 11 (6.5) 1 (0.6)
Lymphocyte low 4 (2.4) 6 (3.6) 1.000
Normal 160 (95.2) 156 (92.9) 1.5 - 4.5 × 103/μl
high 4 (2.4) 6 (3.6)
Mixed cell Normal 160 (95.2) 165 (98.2) 0.26 -1.3 × 103/μl 0.960
high 8 (4.8) 3 (1.8)
Neutrophil Low 13 (7.7) 24 (14.3) 0.233
Normal 136 (81) 124 (73.8) 2.0 – 7.0 × 103/μl
High 19 (11.3) 20 (11.9)
* = significant association. Hematological parameter values less than and greater than the reference intervals are categorized as low and high respectively
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pletion of the 2 month treatment compared with before
initiation of treatment (29.43 ± 7.1 versus 30.13 ± 2.91,
respectively). The difference in MCH and MCHC
among TB treatment naïve and TB patients completedthe intensive phase was found statistically significant
(P ≤ 0.018). In this study, 7.7 % (n = 13) of the TB pa-
tients had low MCV before initiation of anti-TB treat-
ment. The proportion of TB patients with low MCV
was slightly reduced (6 %; n = 10) after completion of
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patients (57.1 %; n = 96) had normal MCH before initi-
ation of treatment and the proportion of TB patients
with normal MCH risen to 108 (62.5 %) after comple-
tion of the intensive phase treatment. Forty-five percent
(n = 75) of the TB patients had low MCHC before initi-
ation of treatment. The proportion of TB patients that
had low MCHC was significantly raised (98.2 %; n =
163) after completion of the intensive phase treatment.
The proportion of TB patients with normal MCHC be-
fore initiation of TB treatment was 53.6 % (n = 90).
However, only 1.8 % (n = 3) of the TB patients that had
normal MCHC before initiation of tuberculosis treat-
ment had also normal MCHC after completion of the
intensive phase treatment.
Red blood cell and Platelet distribution width during
tuberculosis treatment
The mean red blood cell distribution width (RDW)
among treatment naïve TB patients (17.6 ± 7.09 %) was
by far lower than the corresponding RDW (31.9 ±
5.19 fl) of TB patients determined after completion of
the intensive phase of treatment. This difference was
also statistically significant (P = 0.00). Contrary to RDW,
the mean platelet distribution width (PDW) among
treatment naïve TB patients (17.01 ± 4.79 %) was higher
than that of TB patients completed the intensive phase
of treatment (15.7 ± 0.61 %). Moreover, data also showed
statistically significant difference on PDW among treat-
ment naïve TB patients compared with TB patients com-
pleted the intensive phase of treatment (P = 0.00)
(Table 2).
In this study, 70.2 % (n = 118) of TB patients had nor-
mal RDW before initiation of anti-TB treatment. How-
ever, the proportion of TB patients that had normal
RDW was by far reduced to 5.4 % (n = 9) after comple-
tion of the intensive phase treatment. On the other
hand, the proportion of TB patients with high RDW
which was 29.8 % (n = 50) was raised to 94.6 % (n = 159)
after completion of the intensive phase of tuberculosis
treatment. Moreover, data showed statistically significant
difference on the proportion of TB patients with high/
low RDW before initiation and after completion of the
intensive phase of tuberculosis treatment (P = 0.00)
(Table 3).
The proportion of TB patients that had normal PDW
(93.5 %; n = 157) before initiation of treatment was rela-
tively similar to the corresponding proportion of TB
patients that had normal PDW (99.4 %; n = 167) after
completion of the 2 month treatment. Eleven TB pa-
tients (6.5 %) had high PDW before initiation of tuber-
culosis treatment but only 1 patient showed high PDW
after completion of the intensive phase of treatment
and the difference was statistically significant (P = 0.00).Discussion
Tuberculosis exerts incredible varieties of hematologic ef-
fects and hematologic abnormality is a common finding
among TB patients. These abnormalities involves both cell
lines and plasma components. Anti-tuberculosis therapy
has its own spectrum of hematologic toxicity and blood
cell abnormalities [16]. The current study compared the
hematologic profile of HIV negative TB patients before
initiation of treatment and after completion of the inten-
sive phase of tuberculosis treatment.
In the current study, the average RBC of the TB pa-
tients before initiation of anti-TB treatment was rela-
tively similar to that of RBC after completion of the
intensive phase of tuberculosis treatment. The average
RBC of the TB patients were 4.25 × 106 ± 0.83 versus
4.42 × 106 ± 0.824 before treatment and after completion
of the intensive phase treatment, respectively, which is
nearly similar to the lower limits of the reference values
for male and female adults (4.7 and 4.2 million cells per
microliter (cells/μL), respectively). Previously Tsegay
et al. [17] reported reference range of erythrocyte
counts, 5.1 × 1012/l (males) and 4.5 × 1012/l (females) for
healthy adult Ethiopians.
The hemoglobin concentration and packed cell vol-
ume were slightly higher among treatment naïve TB pa-
tients compared with those received anti-TB treatment
for 2 months. However, the proportion of TB patients
with low hemoglobin and hematocrit concentration was
significantly increased (72 %) after completion of the
intensive phase of TB treatment. All chronic infections
including TB can cause anemia [18]. Various pathogen-
esis have been suggested in TB-associated anemia, but
most studies have been shown suppression of erythro-
poiesis by inflammatory mediators as a cause of anemia
[19]. Nutritional deficiency and malabsorption syn-
drome can deepen the severity of anemia [20]. The pos-
sible mechanisms for the development of anemia
during tuberculosis infection may be due to nutritional in-
sufficiency, impaired iron utilization, mala-absorption,
bone marrow granuloma and shortened duration of RBC
survival [21]. Weiss [18], Means [22] and Nemeth et al.
[23] explain the mechanism behind the occurrence of
anemia in pulmonary tuberculosis patients saying that the
invasion of bacteria leads to activation of T-lymphocyte
and macrophages, which induce the production of the cy-
tokines like interferon gamma (IFN-γ), tumor necrosis
factor alpha (TNF-α), Interlukin-1 (IL-1) and interlukin-6
(IL-6) which with their products will cause diversion of
iron into iron stores in the reticulo-endothelial system
resulting in decreased iron concentrations in the plasma
thus limiting its availability to red cells for hemoglobin
synthesis, inhibition of erythroid progenitor cell prolifera-
tion and in appropriate production and activity of erythro-
poietin which may lead to anemia and suboptimal
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high proportion of TB patients with reduced hemoglobin
and hematocrit concentration after completion of the in-
tensive phase of tuberculosis treatment may suggest drug
induced anemia among TB patients. Drugs can induce
variety of hematological disorders affecting RBCs, WBCs
and plateltes. Drug induced syndromes includes hemolytic
anemia, methemoglobinemia, red cell aplasia, sideroblastic
anemia, megaloblastic anemia, polycythemia and aplastic
anemia [8].
The total WBC count of TB patients before initiation
of anti-TB drugs was relatively similar to that of total
WBC count after completion of the intensive phase of
treatment. However, the proportion of TB patients with
low total WBC count was raised from 14.3 % before ini-
tiation of treatment to 18.5 % after completion of the
intensive phase treatment. On the other hand, the pro-
portion of TB Patients with high neutrophil differential
count was increased from 7.7 % before treatment to
14.3 % after completion of the intensive phase of treat-
ment. Nevertheless, there was no leukocytosis neither
before initiation of treatment nor after completion of
the 2 month treatment. In a study designed to assess
the hematological abnormalities of TB patients, Singh
et al. [24] reported a 25 % leukopenia and a 22 % neu-
tropenia among TB patients. Drug induced neutropenia
was also reported in association with various analgesics,
psychotropic’s, anti-convulsions, anti-thyroid drugs, anti-
histaminics, anti-rheumatics, gastro-intestinal drugs, anti-
microbials and cardiovascular drugs [25].
The result of the current study showed that platelet
count was another important hematological profile that
showed significant difference when the count before ini-
tiation of tuberculosis treatment was compared to that
of platelet count after completion of the 2 month tuber-
culosis treatment (P = 0.010). Almost half of the TB pa-
tients that had high platelet count before treatment
showed decreased platelet count after completion of the
intensive phase. This finding is supported by a report
from India and was suggested that decrease in platelet
count could possibly be due to the effect of anti-TB
drugs and immune destruction of platelets [26]. Classical
causes of drug-induced thrombocytopenia are the quinine
and quinine-like drugs [27]. The thrombocytopenia in-
duced by these drugs is caused by antibody that is non-
reactive in the absence of drug, but binds to epitopes on
platelet membrane, glycoproteins IIb/IIIa or Ib/IX, when
the sensitizing drug is present. Vancomycin can also be
associated with marked thrombocytopenia and demon-
strable drug-dependent antibodies in the serum [28].
Other drugs associated with thrombocytopenia include
antimicrobials (sulfanomides, rifampin, linezolid), anti-
inflammatory drugs, anti-neoplastics, anti-depressants,
benzodiazepines, anti-convulsants (carbamazepine, phenytoin,valproic acid) as well as cardiac and anti-hypertensive drugs
[29, 30].
In the current study, the MCV values before and after
treatments were not significantly changed. However, the
differences in the MCH and MCHC values were signifi-
cantly different when the values were compared before
and after completion of the intensive phase of TB treat-
ment. Previous reports showed that the red cell indices
in the untreated male pulmonary TB patients showed
lower values as compared to normal males. In addition,
it was also found that the MCH and MCHC among male
pulmonary TB patients were significantly lower when
compared with normal males [31, 32]. Different study
reports showed that after anti-tuberculosis treatment
with streptomycin, rifampicin and isoniazid, the RBC in-
dices were affected and reached closer to normal values.
Moreover, RBC morphology in pulmonary TB patients
was found to be mainly normocytic normochromic type
and during medication, the blood film showed normo-
chromic pictures [31, 33, 34] which suggests the effects
of tuberculosis treatment on the restoration of RBC
morphology.
The mean RDW of TB patients determined after com-
pletion of the intensive phase of treatment (31.9 ±
5.19 %) was significantly different from the correspond-
ing RDW of treatment naïve TB patients (17.6 ± 7.09 %).
Opposite to the RDW, the PDW among treatment naïve
TB patients (17.01 ± 4.79 %) was higher than the PDW
of TB patients measured after completing the intensive
phase of treatment (15.7 ± 0.61 %). Moreover, TB pa-
tients that had high PDW before treatment (n = 10)
showed reduced PDW after completion of the 2 month
anti-TB treatment. Red cell distribution width and PDW
measure the variation of RBC and platelete volume. The
normal reference range of RDW-CV in adult humans
was reported 11.5 to 14.5 % [35] while that of PDW 9–
16.56 % for men and 8–13.3 % for women [36]. Now-
adays, RDW is used to diagnose anemia. Domingo et al.
[37] reported greater decrease in hemoglobin concentra-
tion in patients with higher values for RDW. Red cell
distribution width is often used to differentiate anemia
of mixed causes from anemia of a single cause. There
are reports that documented deficiency of vitamin B12,
or folate produce macrocytic anemia (large cell anemia)
in which the RDW is elevated in roughly two-thirds of
all cases [38]. However, varied size distribution of RBC is
the hallmark of iron deficiency anemia, and as such
shows increased RDW in virtually all cases [39]. Long
term exposure to anti-tuberculosis medication increases
the risk of adverse drug reactions and toxicity. Isoniazid
and rifampicin may directly cause hemolytic anemia, as
can pyrazinamide cause sidroblastic anemia [40]. Others
have suggested that anemia is seen as part of the clinical
manifestation of tuberculosis and as a consequence of a
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higher predisposition to develop gastro-intestinal ab-
sorption problems, consequently leading to anemia [20]
and elevated RDW is associated with anemia. At a con-
dition when there is microcytic RBCs produced prior to
treatment and normocytic RBCs produced after com-
pletion of treatment in the circulation leads to high size
variation (increase RDW value). Lee et al. [20] showed
that anemia is a common hematological abnormality in
patients and Baynes et al. [19] states that RDW values
in chronic inflammatory disorder like tuberculosis simi-
lar with the RDW values occurring in iron-deficiency
anemia which is in line with the current study.
Platelet distribution width directly measures the vari-
ability in platelet size and has been used to differentiate
disorders of platelets such as essential thrombocyth-
emia from reactive thrombocytosis [41]. In the present
study, PDW of TB patients was significantly reduced
after taking anti-TB drugs for 2 months. Previously,
Tozkoparan et al. [42] reported that there were signifi-
cantly higher PDW values (40 ± 23.5) among TB patients
which decreased significantly with anti-tuberculosis ther-
apy. Thrombocytopenia is a serious side effect that po-
tentially caused by anti-TB drugs which occurs mostly
due to rifampicin (RIF) [43]. The main mechanisms of
thrombocytopenia are decreased production or in-
creased destruction of platelets. The drug binds non-
covalently to membrane glycol-proteins to produce
compound epitopes or induce conformational changes
which antibodies are specific. In addition, RIF-dependant
antibodies attach to thrombocytes and cause increased de-
struction [44]. However, the exact mechanism of INH-
induced thrombocythemia is not known.
The result of this study showed that the Hgb concen-
tration, HCT, PLT and PDW values were reduced after
completion of the intensive phase of tuberculosis treat-
ment. This is due to the fact that iron is critical for
Mycobacterium tuberculosis growth in macrophages in
turn causes iron deficiency anemia. After the intensive
phase treatment, there will be sufficient iron in the
body and starts production of normal erythrocytes. This
study finding is supported by Tozkoparan et al. [42]
that indicates significantly lower PDW values with anti-
tuberculosis therapy. Also another study by Sahin et al.
[45] indicates that reactive thrombocytosis and PDW
develop frequently in PTB and there is a relation with
acute phase reactants, which is the inflammatory re-
sponse and decreased after treatment.
Conclusion
The levels of hemoglobin, hematocrit and platelet count
of the TB patients were significantly lowered after com-
pletion of the intensive phase of TB treatment compared
with the corresponding values before initiation of anti-TB treatment. The RDW and PDW also showed signifi-
cant variation before initiation and after completion of the
2 month tuberculosis treatment. The varied hematological
abnormalities observed in TB patients after intensive
phase tuberculosis therapy suggests the need for continu-
ous monitoring and evaluation of TB patients for adverse
hematological abnormalities during tuberculosis treat-
ment. Anemia was found to be one of the most com-
mon hematological abnormalities among patients
taking anti-tuberculosis treatment. Thus anemia and
thrombocytopenia should be regularly checked during
tuberculosis treatment.
Limitation of the study
The limitation of this study was the relatively small sam-
ple size which is the result of the nature of the study as
longitudinal study are time consuming and costly. We
were also unable to determine the effect of anti-TB
drugs after completion of the 6 month treatment.
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